HC Wainwright Forecasts Kairos Pharma Q1 Earnings

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Kairos Pharma in a note issued to investors on Thursday, April 2nd. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright also issued estimates for Kairos Pharma’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.09) EPS and Q4 2026 earnings at ($0.12) EPS.

Kairos Pharma Stock Performance

Shares of KAPA stock opened at $0.58 on Friday. The company has a market cap of $12.44 million, a P/E ratio of -1.94 and a beta of 1.97. The firm has a fifty day moving average price of $0.61 and a 200 day moving average price of $0.83. Kairos Pharma has a 12 month low of $0.40 and a 12 month high of $2.11.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.07) EPS for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC purchased a new position in shares of Kairos Pharma in the 3rd quarter valued at about $27,000. XTX Topco Ltd boosted its holdings in Kairos Pharma by 290.8% in the fourth quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock valued at $34,000 after purchasing an additional 36,086 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Kairos Pharma in the third quarter valued at approximately $54,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.